GlassScriptPhysician profile
Lawrence J Amato
NPI 1528020690
$16,749.51
in general payments reported to CMS, 2019-2025
57 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,237 · 2020: $2,512 · 2021: $2,900 · 2022: $2,751 · 2023: $2,085 · 2024: $2,492 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,341 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,341.36 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,103.78 | 2019-2025 | Tezspire, Airsupra, Farxiga |
| Abbvie INC. | $1,625.65 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,587.14 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Amgen INC. | $1,200.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $1,034.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $755.06 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $750.17 | 2019-2022 | |
| Electromed, INC. | $615.58 | 2021-2025 | Smartvest |
| Amarin Pharma, INC. | $569.75 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $550.76 | 2020-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $529.48 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $470.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $434.76 | 2019-2021 | |
| Allergan, INC. | $401.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.18 | 2019-2024 | Trulance, Xifaxan, Plenvu |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Amato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.